ERBB2 and triple-negative breast carcinoma: However, if these cases are delineated into the distinct subtypes, EpCAM expression is associated with an unfavourable prognosis in the basal like triple negative breast cancers and luminal B subtypes, whereas in the human epidermal growth factor receptor 2 (HER2+) subtype, it is associated with a favourable prognosis [11].